engraftment syndrome following asct in patients with checkpoint inhibitor treated hodgkin lymphoma
Published 7 months ago • 157 plays • Length 4:40Download video MP4
Download video MP3
Similar videos
-
5:46
the use of allogeneic transplantation in the era of checkpoint blockade therapy in hodgkin lymphoma
-
2:11
strategies used to enhance checkpoint inhibition in hodgkin lymphoma
-
2:54
the management of post-transplant complications in hodgkin lymphoma
-
1:27
the promise of novel checkpoint inhibitors for the treatment of hl
-
3:12
hodgkin lymphoma remission prolongation: post-asct strategies
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
10:43
immunotherapy and lymphoma treatment
-
2:07
the role of checkpoint inhibitors in classical hodgkin lymphoma
-
1:51
checkpoint inhibition in the treatment of mpns
-
2:34
r/r lymphoma: checkpoint blockade and transplantation
-
1:33
outcomes of hodgkin lymphoma patients who receive a second asct
-
2:13
reinforcing transplantation with consolidation therapy in hodgkin lymphoma
-
2:00
updates on treatment methods for hodgkin lymphoma
-
6:16
overview of novel restore and target treatment approach to classical hodgkin lymphoma
-
5:01
relapsed & refractory classic hodgkin lymphoma
-
1:43
maintenance nivolumab in post-stem cell transplant hodgkin lymphoma
-
2:03
novel therapeutic agents in the treatment of hodgkin and non-hodgkin lymphoma
-
3:51
novel developments in relapsed/refractory hl: checkpoint inhibitors, bispecifics and car-t cells
-
3:34
effect of time to relapse on os in mcl following autohct
-
1:00
efficacy of haploidentical sct for r/r classical hodgkin lymphoma
-
1:37
the role of ctdna in hodgkin lymphoma
-
1:59
hodgkin lymphoma: prognostic markers in the era of novel treatments